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Abstract
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This study used Monte Carlo simulations to examine the ability of the two-stage least-squares
(2SLS) estimator and two-stage residual inclusion (2SRI) estimators with varying forms of
residuals to estimate the local average and population average treatment effect parameters in
models with binary outcome, endogenous binary treatment, and single binary instrument. The
rarity of the outcome and the treatment were varied across simulation scenarios. Results showed
that 2SLS generated consistent estimates of the LATE and biased estimates of the ATE across all
scenarios. 2SRI approaches, in general, produced biased estimates of both LATE and ATE under
all scenarios. 2SRI using generalized residuals minimized the bias in ATE estimates. Use of 2SLS
and 2SRI is illustrated in an empirical application estimating the effects of long-term care
insurance on a variety of binary healthcare utilization outcomes among the near-elderly using the
Health and Retirement Study.

1.

INTRODUCTION

Author Manuscript

Instrumental variables (IV) methods are used to obtain causal estimates of the effects of
endogenous variables on outcomes using observational data. These methods mediate
potential bias from unmeasured confounders affecting observed treatment through
identifying and specifying an instrumental variable, which may represent a “natural
experiment” affecting treatment through satisfying two principle assumptions: the
instrument is sufficiently correlated with the endogenous variable (strength), and the
instrument is uncorrelated with the error term in the outcome equation (validity). IV
methods are usually implemented using a two-stage approach where the first-stage estimates
an expectation of the endogenous variable conditional on measured confounders and one or
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more instrumental variables. The second stage model then predicts outcomes as a function of
the estimated treatment values from the first-stage, measured confounders, and potentially
other control variables.

Author Manuscript

In what has been popularly dubbed as the two-stage least-squares (2SLS) approach, the first
and second stage models are parametrized using ordinary least squares regression, where the
model fit is chosen through minimizing the sum of squared residuals from linear models.
The 2SLS approach is a special case of the more general two-stage predictor substitution
(2SPS) method, which follows the procedure described above but may apply alternative
methods for estimating first- and second-stage models. Alternatively, one can obtain the
residuals from the first stage regression and then run the second stage regression with the
original endogenous variable, observed confounders and the residuals from the first stage as
an added covariate. This approach, known as the two-stage residual inclusion (2SRI)
approach, is analogous to the 2SLS approach when both first- and second-stage models are
linear.

Author Manuscript

These estimation methods were originally derived in a linear setting with continuous
endogenous treatments and continuous outcome measures. The target parameter for these
estimations is the average causal effect, which is the average of the partial derivative of a
continuous outcome with respect to a continuous endogenous variable. However, these
estimators but are often applied to what may be considered an inherently non-linear setting,
such as with binary treatment or outcome measures. When treatment (exposure) or outcome
is binary and therefore has a conditional expectation that follows a probability scale, a nonlinear model featuring a convenient cumulative density function (CDF) is often used to
model the conditional mean of the treatment indicator in the first-stage or outcome in the
second-stage. Popular approaches include using probit or logit regression models.
In these settings, it is well established that the 2SPS approach produces biased estimates of
the population average treatment effect (ATE) (Blundell and Powell 2001; Terza et al. 2008).
Under full parametric assumptions of joint-normality, bi-variate probit models can be used
to model the two stages simultaneously (Bhattacharya et al. 2006) and estimate the ATE

Author Manuscript

Alternatively, it has been suggested that nonlinear 2SRI is the appropriate approach for
estimation when first- or second-stage models have a dependent variable that is binary or
otherwise suited for non-linear regression; especially when full parametric assumptions,
where statistical joint distribution of error terms of the exposure and outcomes are specified,
are not wanted (Blundell and Powell 2003, 2004; Terza et al. 2008). Nonlinear 2SRI
methods identify the ATE through relying on the concepts that support control function
methods (Blundell and Powell 2003, 2004), which were developed in the context of
continuous endogenous variables. However, applicability of nonlinear 2SRI to models with
binary endogenous treatments remains contentious.
Finally, with a non-linear data-generating process for outcomes, treatment effects are
heterogeneous by construction. This raises complexity and confusion in that the specific
treatment effect parameter identified by the 2SLS or 2SRI approaches may differ and
generally depends on whether treatment effects are heterogeneous across the population and
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vary across levels of observed or unobserved confounders (aka essential heterogeneity). In
such a situation, it is well–established that traditional IV approaches such as 2SLS identify
an average treatment effect across only the subgroup of “marginal” individuals whose
treatment choices were affected by changes in the specified instrumental variable(s)
(Heckman 1997; Heckman et al. 2006, Basu et al. 2007). When the instrumental variable is
binary (which is the focus of this paper), this effect is known as the local average treatment
effect (LATE) (Imbens and Angrist 1994). It is an average of the treatment effects for each
individual at the margin, or the marginal treatment effects, whose treatment choice would be
affected by the change in the level of the instrument (Heckman 1997; Heckman et al. 2006,
Basu et al. 2007; Kowalski 2016). Both 2SLS and the analogous strictly linear application of
2SRI will generate consistent estimates of LATE as long as the linear mean model
specifications in both stages are correct.1

Author Manuscript
Author Manuscript

Terza et al. (2007, 2008) claimed that nonlinear 2SRI, but not 2SLS or 2SPS, produced
consistent estimates of ATE in models with inherently nonlinear dependent variables.
However, it is not clear which treatment effect parameter is being estimated under a 2SRI
approach for a binary treatment. Particularly in applications with binary IVs, the 2SRI
approach relies on functional form assumptions for identification (as explained below) that
are difficult to test in most applied setting and many analysts, especially economists, have
favored the 2SLS approach regardless of whether treatment and outcome are continuous or
binary. As such, many questions remain about the best approaches to IV estimation with
such data. On one hand, linear probability models may not provide a good fit to the data,
especially when treatment or outcome variables are “rare” or otherwise imbalanced in
nature, which in turn may lead to imprecise estimates. On the other hand, probit and logit
models may provide a better fit to observed data overall but generate biased estimates
depending on the support of the residual distribution (across all X’s).
For example, Chapman and Brooks showed that small changes to the simulation settings of
Terza et al. (2007) resulted in different results and conclusions about the properties of 2SLS
and 2SRI. They showed that 2SLS produced consistent estimates of LATE across alternative
scenarios while 2SRI estimates were not generally consistent for either ATE or LATE.
However, the evidence produced by Chapman and Brooks is limited in that their scenarios
all included two continuous instrumental variables and had treatment and outcome rates near
50%, a setting that may have inadvertently favored the 2SLS method.

Author Manuscript

Moreover, there is a debate in the health econometrics literature about the right form of the
residual to be used in 2SRI approaches. Garrido et al. (2012) compared results from 2SRI
models with different versions of residuals when applied to health expenditure data. They
found that results varied widely depending on the type of residuals they use in the second
stage. They raised the concern that raw residuals may not be the right control function
variable. However, there is no theoretical rationale as to why different forms of the residual
matter and the authors did not perform simulations to show which one is better. Chapman &

1The LATE effect is non-parametrically identified in a 2SLS setting within any cell defined by levels of all observed covariates X
(Imbens and Angrist 1994). However, in a regression setting with many X’s, where a full saturated model is typically not used, the
consistency of estimating LATE would rely on the appropriateness of the linear model specification.
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Brooks’ only considered 2SRI with raw residuals when showing general inconsistency of
2SRI for ATE and LATE. Further, Chapman & Brooks did not report coverage probabilities
for their estimates, a necessary component for making comparisons on properties of 2SLS
and nonlinear 2SRI methods and for considering potential strengths and limitations of these
approaches in practice.

Author Manuscript

In this paper, we try to provide theoretical and empirical evidence to inform these debates.2
We first extend the recent assessment conducted by Chapman & Brooks using a simple
scenario with binary outcome, a binary treatment that is made endogenous by a continuous
unobserved confounder, binary instrument, and a binary measured confounder. There is an
abundance of examples in the applied health literature where such a full binary setting is of
relevance. Our empirical example illustrates this case. 2SRI and 2SLS methods can also be
applied to other settings such as for count data and expenditure models. This paper does not
say anything about the performance of these estimators in those settings.
After a theoretical discussion on the properties and expected behaviors of alternative
estimators, we test the capability of 2SLS and alternative specifications of 2SRI methods for
estimating alternative average treatment effect concepts across a range of simulation
scenarios varying by the rarity of the treatment and the outcomes using extensive MonteCarlo simulation exercises.

Author Manuscript

Results show that the 2SLS method with binary IV produced consistent estimates of LATE
across the entire range of rarity for either treatment or the outcome. The rarity of either did
not affect the coverage probabilities of these estimators. In contrast, the 2SRI approach with
any residuals studied was a biased estimator for LATE. In principle, nonlinear 2SRI
estimators are designed to estimate the ATE parameter. However, 2SRI estimates of ATE
were also generally biased, with the level of bias varying by residual form and outcome
rarity. General conclusions from results of these simulation models are consistent with those
of the more limited scenarios considered by Chapman & Brooks. Among 2SRI models,
those using generalized residuals were most often least biased in estimating ATE, though
2SRI with Anscombe residuals generated less biased estimates in scenarios with very rare
outcomes (<5%). Implications of these results are discussed.

Author Manuscript

Finally, we examined the implications of model choice using an empirical setting that
resembles the simulated scenario with endogenous binary treatment, binary outcomes, and
binary observable confounders. The alternative instrumental variable methods were applied
to evaluate the effect of long-term care insurance on a variety of health care utilization
outcomes using tax treatment as an instrument for long-term care insurance holding, as has
been validated in the literature (Goda 2011; Konetzka, et al. 2014, Coe, Goda and Van
Houtven 2015). The results from applying the alternative estimators are discussed in the
context of our simulation results.

2There are other forms of estimators that deal with a binary outcome and a binary endogenous treatment model, such as a GMM
approaches (McCarthy and Tchernis 2011) and semi-parametric estimators (Abadie 2003; Abrevaya et al. 2009, Chiburis 2010; Shaikh
and Vytlacil 2011). However, these estimators are not as popular as the 2SLS and the 2SRI approaches and so we do not cover them in
this paper.

Health Econ. Author manuscript; available in PMC 2019 June 26.

Basu et al.

Author Manuscript

2.

Page 5

ECONOMETRIC THEORY & METHODS
In what follows, we provide an intuitive explanation of the underlying theory of these
methods rather than the full formal theory
Consider the binary structural response model
yi = 1 yi* > 0 ,

(1)

where the latent variable yi* follows a linear model of the form
yi∗ = xiβ + ui,

(2)

Author Manuscript

where xi is a row vector of covariates and ui is a stochastic disturbance term for individual i.
Throughout this section, bold-face is used to represent a vector. If ui is independent of xi, a
single index regression model such as:
E yi | xi = G xiβ

G a = Pr ui > − a

(3)

can be used to obtain consistent estimates of β. However, it may often be the case that ui is
not independent of xi because some component of xi, say di, is determined jointly with yi*
such that

Author Manuscript

xi = di, wi , yi = 1 diβ1 + wiβ2 + ui > 0 , and di ⊥ui,

(4)

where ⊥ indicates statistical independence. Let the reduced form of di, which we denote to
be the endogenous binary treatment variable, be given as
di

= E di | wi, zi + vi
= λ wi, zi + vi

(5)

Author Manuscript

where zi = vector of instrumental variables, λ is the true function through which di is
determined by wi and zi, vi is a stochastic disturbance term, and E(vi | wi, zi) = 0 by
construction. It is assumed throughout that expectation of d is a non-trivial function of z
given w.
For evaluation research, interest generally lies in estimating β parameters or, more
specifically, the components of β that represent the causal effect of an exogenous shift in
treatment, di, on the response probabilities. The interpretation of those parameters of interest
then must be considered. The broadest and perhaps most intuitive treatment effect parameter
is the average treatment effect (ATE), which represents the mean change in outcome that
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would be realized if everyone in a target population changed from not receiving treatment to
receiving treatment. The ATE can be written as
ATE(w)

=

∫

u ∈ U |w

E yi | wi, ui, di = 1 − E yi | wi, ui, di = 0

⋅dF(u | w)

(6)

= G β1 + wiβw − G wiβw

where ATE (w) represents the conditional average treatment effect for a sample, which may
be distinct in the mix of characteristics w.

Author Manuscript

If it is the case that treatment effects are heterogenous across the population and this
heterogeneity is related to treatment choice (i.e., essential heterogeneity) then treatment
effectiveness will vary over levels of ui when components of w are unmeasured by the
researcher (i.e., there are unmeasured confounders). As a result, identification of ATE will
require strong assumptions. First, the ATE can be estimated through identification of the
function represented by G(.), which is to akin to identifying the full parametric distribution
of ui. In the absence of full parametric assumptions, the ATE can be identified in special
cases using instrumental variables methods, where the specified IV(s) fully identify the
conditional distribution of ui | vi, which can then be integrated over the distribution of vi
identified in the IV-based first-stage model. More simply put, the specified IV(s) must be
considered as potentially influencing treatment choice for all types of individuals in the
sample, defined by their levels of observed and unobserved characteristics. These IV
assumptions may be particularly difficult to satisfy when a single binary instrument is used,
as only two points of support in the distribution of vi are identified non-parametrically.

Author Manuscript

More generally, as Imbens and Angrist (1994) have shown, the IV effect estimated using a
single binary IV, zi, is referred to as the local average treatment effect (LATE) and is given
as:
LATE w = E yi | wi, zi = 1 − E yi | wi, zi = 0 / E di | wi, zi = 1 − E di | wi, zi = 0

(7)

Author Manuscript

The LATE reflects the average causal effect of di on the probability of yi among those
(marginal) individuals whose treatment statuses would likely change with a change in the
level of the instrumental variable (Angrist & Imbens 1994, 1996; Heckman 1997). The
LATE parameter is only “locally” interpretable in the context of the instrument specified.
Even with very strong instruments that lead all patients in the sample to be marginal, LATE
will not often converge to the ATE because, unlike randomization, the instrument may put
more weight on some marginal patient than others. Therefore, since it is often difficult to
identify the marginal patients directly (i.e., to know for whom the instrument affected
choice), it may also be difficult to understand to whom the estimate applies (Heckman 1997;
Newhouse and McClellan, 1998). In some cases where a binary IV is related to a specific
policy, LATE may be interpretable as the effect of changing di among those individuals who
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would be induced to change their treatment status by the policy (Heckman et al. 2006).
Naturally, if the true treatment effect is constant then the true LATE and ATE are the same.
The following discussion focuses on three popular approaches for estimation of mean effects
on response probabilities from an instrument-driven exogenous shift in the treatment di: the
fully parametric bivariate probit (BVP) model, the semi-parametric residual inclusion (2SRI)
approach, and the linear two-stage least squares (2SLS) approach. Each of these methods
employ different assumptions and attempt to identify different parameters. In fact, Chiburis
et al. (2012) have argued that many of the documented differences in the treatment effect
estimates from 2SLS and bi-variate probit models in the literature may be driven by the fact
that they are estimating different parameters to begin with. We now look at these estimators
in detail.

Author Manuscript

2.1

Approach 1 (Fully parametric): e.g. Bivariate-Probit
If the joint distribution of the structural error term ui and the reduced form error term vi were
parametrically specified (e.g. Gaussian), and λ(wi, zi) is parametrically specified, then under
some normalization of the Var(ui) (Blundell and Smith 1986),
E yi | di, wi, vi

= Pr ui > − diβ1 − wiβ2 | vi
= Φ diβ1 + wiβ2 + ρvi ,

(8)

Author Manuscript

where ρ is the vector of population regression coefficients of ui on vi. The parameters β, λ(.)
and ρ can be estimated using maximum likelihood estimation. When both yi and di are
binary, this approach can be implemented using a bivariate probit regression (Heckman
1978). However, bivariate probit models can be sensitive to heteroscedasticity and are
usually more robust when treatment probabilities approach 0 or 1 (Chiburis et al. 2012). If
the underlying distributions are correctly specified, this method structurally recovers the
average treatment effect (ATE) parameter since ui | vi, identified through the IV, is
structurally linked to ui through the parametric assumption.
The sample analog for the population treatment effect parameter identified by this approach
is given by:
EW{Ev{Φ(1 ⋅ β1 + wiβ2 + ρ ⋅ vi) − Φ(0 ⋅ β1 + wiβ2 + ρ ⋅ vi)}},

(9)

Author Manuscript

where · indicates that these quantities have been estimated from the data at hand.
2.2

Approach 2 (Semi-parametric): e.g 2SRI
The semi-parametric approach uses estimates of the reduced form error term, vi, to control
for endogeneity of di in the outcomes structural model (Blundell and Powell 2004). The
identification of β1 and the distribution functions of the error term, ui, is through
distributional exclusion restrictions, the first of which requires that the dependence of ui on
each of di, wi and zi are completely characterized by the reduced form error vector vi:
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ui|di, wi, zi

ui|di, wi, vi
ui | vi

(10)

Under this assumption,
E yi | di, wi, vi = Pr ui ≤ − diβ1 − wiβ2 | di,wi, vi

(11)

= F diβ1 + wiβ2 | vi .

where F(.) is the conditional c.d.f. of -ui given vi.

Author Manuscript

The marginal distribution function G(.) with respect to -ui could be identified using a control
function approach such as (Blundell and Powell 2004):
G diβ1 + wiβ2 =

∫ F dβ

i 1 + wiβ2, v1

HV ,

(12)

Author Manuscript

where Hv is the distribution function of v. Consequently, ATE can be identified using (6).
Note that, unlike the fully parametric approach, one can be agnostic about the parametric
distribution of ui and vi as long as the distributional exclusion criterion is met. However,
Blundell and Powell’s (2003) identification relies on a continuous vi. Moreover, the
identification of ATE relies on the fact that the error term in the outcomes model is
additively separable. These conditions allow for a counterfactual to be determined without
the need for any additional functional form assumptions given that the β are consistently
estimated. However, in non-linear models, such as those in (2), these counterfactuals
inherently depend on the functional form assumption of the control function.
For example, in practice, this approach is implemented through “residual inclusion”, which
follows estimating the error term in the first–stage regression and then including these
estimated residuals as a covariate in the second-stage outcomes regression. A recycled
predictions approach can then be used to recover the marginal effect of di on E(yi).

Author Manuscript

However, when implementing this approach for a binary treatment variable, the residuals
from the first stage would always be positive for treatment recipients and negative for nonrecipients. Hence, in a non-linear outcomes model, the conditional treatment effect,
conditional on any level of the estimated vi (say, vi), must be obtained via extrapolation.
Figure 1 illustrates this idea for a group of individuals with the same wi, which is kept
implicit, but different values of zi, which leads to difference values of vi. Suppose the
residuals among treatment recipients are 0.1, 0.2, 0.3, 0.4, 0.7 and those among nonrecipients are −0.1, −0.2, −0.3, −0.4, −0.7. Conditional on a positive level of the residual vi+,
E y|d = 1, vi + = E y1 | vi + is obtained from the data where y1 is the potential outcome

under treatment. However, the counterfactual outcome, i.e. the corresponding potential
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outcome y0 for treatment recipients, which are supposed to be estimated from the outcomes
of similar patients under no treatment, cannot be directly estimated as there are no nonrecipients that have a positive level of the residual by construction.
Once the parameters of the F(), the CDF-based regression function used to model the binary
outcome as a function of d and the residuals, are estimated, the counterfactual outcomes for
treatment recipients over the distribution of positive residuals has to be obtained via
extrapolation of the functional specification of F() over the positive residuals and turning off
the indicator d to 0.. Similar extrapolation is required for estimating the counterfactual
outcomes y1 for treatment non-recipients over the distribution of negative residuals. Figure
1(a) illustrates this extrapolation. The overall treatment effect is then obtained by averaging
the conditional treatment effects obtained over the distribution of vi.

Author Manuscript

Symmetry in the distribution of vi, to the extent that it can be attained, can facilitate this

Author Manuscript

extrapolation. Most forms of residuals used in non-linear settings attempt to mimic a normal
distribution. Alternate forms of residuals, such as standardized, deviance, Anscombe, and
generalized (Gourieroux et.al., 1987), may also be used in the residual inclusion approach
and have been explored Garrido et al. 2012). When estimated by a nonlinear approach, such
as probit or logit, raw-scale residuals for a binary treatment variable will always lie between
0 and 1 in absolute values. Therefore, each type of residual transformation is likely to spread
the support of the residual distribution on the real line. For example, if predicted Pr(d|z) =
0.4 and 0.7 for two observations with d = 1, then the raw-scale residuals will be 0.6 and 0.3
respectively, but the standardized residuals ( = (d − p(z))/ (p(z)(1 − p(z))) will be 1.22 and
0.65 respectively. Consequently, standardized residuals may provide a better fit to the
outcomes data and increase the robustness of extrapolations. For example, when the
treatment is rare, the raw-scale residuals on either the negative or the positive side are likely
to be far away from zero. Transformation can help these residuals to spread out, so as to
increase accuracy when estimating the functional form of the outcome conditional on these
residuals. A priori, it is difficult to predict what form of residuals from a binary treatment
model would best approximate the non-separable error term in the outcomes equation.
It is worth reiterating that a central problem, beyond the issue of non-overlap in support of vi
as discussed above, when the instrumental variable is also binary is that only two points on
the support of vi are identified for any level of w. Model fit and extrapolation is based only
on those two points in the support for vi .

Author Manuscript

2.3

Approach 3 (Non-parametric): e.g. 2SLS
Distinct from BVP and 2SRI approaches discussed above, which are designed to identify the
ATE, a 2SLS approach is designed to estimate the LATE parameter. A 2SLS approach
attempts to estimate the LATE from the data non-parametrically by estimating the slope of
outcomes and exposure, conditional on the instrument. In the case of a single binary
instrument, this slope is based upon the two points of support identified by the two levels of
the instrument. That is, it plugs in the sample analogs of the numerator and the denominator
in the LATE parameter defined above. However, this process assumes that the mean
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outcomes and the exposure models are linear in terms of wi.3 When one or both of these
linear specifications are violated, 2SLS may be a biased estimator for the outcome
probabilities (Horace and Oaxaca 2006). While this could, in turn, induce bias in the
estimation of LATE, some have suggested that risk of such bias is minimal in many applied
settings and concerns are exaggerated. (Angrist and Fernandez-Val 2001)

Author Manuscript

The 2SLS approach of linear IV models can be viewed as a special case of control function
methods (Telser 1964), where both first and second stage regressions are linear. However,
since 2SLS approaches rely only on mean–independence requirements, and not on the full
conditional independence of the distribution as in (8), demands the “correct” specification of
the first-stage to provide consistent estimates of the second-stage parameters (Blundell and
Powell, 2004). However, this requirement seems to apply mostly for the estimation of ATE;
as the LATE value is not necessarily equivalent or determined by the true structural
parameters under essential heterogeneity. It is unclear how violation of this requirement
affects estimation of LATE. We expect that for a binary treatment in the first stage, a linear
approximation of the conditional mean is likely to be most appropriate when the mean
treatment is close to 50%. Chapman and Brooks (2016) simulation results showed that 2SLS
methods produced unbiased estimates of the IV effect (i.e weighted average of LATEs
defined by the continuous IVs that they use) in models with treatment rates near 50%, but
did not consider binary instruments.

Author Manuscript

These discussions establish the rationale for the simulations in this paper. It is conjectured
that 2SRI approach applied to binary endogenous variables can produce biased results when
extrapolations are not appropriate. Alternative versions of the residuals could improve the
performance of 2SRI approaches through mutating the scale of the residual distribution
used, which could influence the estimation of the underlying structural functions through the
2SRI approach as was observed in Garrido et al. (2012). Second, when the endogenous
binary variable becomes rare, the linear model specification in the first-stage could break
down, resulting in biased estimation of second-stage parameters in the 2SLS approach.
These biases could then compound biases from misfit of the linear model to rare outcomes
in the second-stage.

3.

SIMULATIONS

Author Manuscript

We consider the simplest case where we have a binary outcome (yi), a binary treatment (di),
three binary controls (wi) and a binary instrument (zi). We chose three binary controls so that
the residuals from the first stage regression have at least thirty unique values in their support.
The central questions we try to answer with these simulations are: Can linear approximation
(2SLS) provide consistent estimates of the LATE for a binary outcome/binary endogenous
variable model? What form of residuals are most suited to a correctly specified nonlinear
2SRI (Probit-Probit) approach? How do the results change if outcomes (yi) and/or treatment
(di) become rare?

3There can certainly be a more elaborate model building exercise that can overcome this problem, but such exercises are seldom found
in the economics and health economics literature. In any case, such exercises typically lead one away from a simple linear model into
the realm of non-linear models.
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The data generating processes (DGPs) are described below (subscripts i are suppressed for
clarity).
3.1

Exposure (treatment) DGP
d∗ = α0 + α1 ⋅ w1 + α2 ⋅ w2 + α3 ⋅ w3 + αz ⋅ z + αU ⋅ wU − ω ,

(13)

Author Manuscript

where (α1, α2, α3) = (0.5, 1, 2), αU = 1, αZ = 1. Observed variables w1, w2, w3 and z are all
binary variables with mean equal to 0.5, generated by dichotomizing standard normal
variables around the value of 0. Together, (αU· wU – ω) represents the empirical error term
for the treatment model and consists of the binary unobserved confounder, wU, which is also
based on dichotomizing a Normal (0,1), and the continuous model disturbance term, ω ~
Normal(0,1). Observed treatment, d, is derived from the index function (d* > 0) and Pr(d) =
Φ( (α0 + 2.25)/√3.5625)). We vary the model intercept, α0, to take on values of −2, −1.25,
−0.3, 0.5, and 1.5 which correspond to Pr(d) = 0.55, 0.70, 0.85, 0.93, and 0.995 respectively.
3.2

Outcomes DGP
y* = β0 + βD ⋅ d + β1 ⋅ w1 + β2 ⋅ w2 + β3 ⋅ w3 + βU ⋅ wU − ε

(14)

Author Manuscript

Together (βU· wU – ε) represents the empirical error term, u, from the theoretical outcomes
model under Section 2. Across all simulation models, true values of coefficients (β 1, β 2,
β3) were set to (1,1,1), the coefficient for the unmeasured confounder, βU, was set to 2, and
coefficient on treatment, βD, was set to 1. The model disturbance term ε ~ Normal(0,1) and
Pr(y|d) = Φ( (β 0 + β D· d + 1.5)/√5.75)). We vary β 0 across simulations to take on values
of −2, 0.5, 1.5, and 2.5 which correspond to Pr(y) = 0.51, 0.82, 0.93 and 0.96 respectively.
3.3

Target parameters
The primary target parameters were the ATE and the LATE. True values for the ATE and
LATE concepts were calculated in each simulation as:
ATE = E y | d = 1 − E y | d = 0 = Φ β0 + 2.5 /

5.75 − Φ β0 + 1.5 /

Author Manuscript

5.75

(15)

LATE = Ew [E(y | z = 1, w) − E(y | z = 0, w)]/[E(d | z = 1, w) − E(d | z = 0, w)]

(16)

where w = (w1, w2, w3, wu). The true value of the LATE parameter was simulated based on
100 samples of 1 million observations each.
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Simulations
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Estimates were generated using Monte-Carlo simulation methods, using 1,000 samples of
50,000 observations each to mitigate finite sample issues and also to align our simulation
with our empirical example. For each of the 1,000 simulated samples, 500 bootstrap resamples were drawn and used to calculate standard error and coverage values. Percent bias
was calculated as (Δk - LATE)*100/LATE or (Δk - ATE)*100/ATE averaged over all
simulated samples, where Δk is the estimated treatment effect for sample k. The coefficient
of variation is based on the standard deviation of the mean estimates across the 1,000
Monte-Carlo samples divided by the average of the mean estimates from those samples.
Finally, coverage probabilities for LATE and ATE were determined by averaging I ((Δk –
1.96* SEk) ≤ LATE ≤ (Δk + 1.96* SEk)) and I ((Δk – 1.96* SEk) ≤ ATE ≤ (Δk + 1.96* SEk)),

Author Manuscript

respectively, across all 1,000 samples, where I() is an indicator function and SEk is the
sample-specific standard error obtained via bootstrap.
Simulations were repeated using a sample size of 5,000 to magnify any finite sample issues,
and those results are presented in the appendix.
3.5

Estimators
We compared the following estimators:
1.

IV regression with LPM (2SLS)

2.

Probit-Probit 2SRI with

Author Manuscript

a.

raw residuals as (di − d),

b.

standardized (Pearson) residuals given by (di − dı)/ {(1 − dı)dı},

c.

d.

deviance residuals, given by 2 yilog

di
dı

+ (1 − di)log

1 − di
1 − dı

and

Anscombe residuals, (A(di) − A(dı))/[A′(dı) {(d−dı)dı}], where
2 2

2 2

−1 6

A(di) = (B(di, 3 , 3 ) −B(d, 3 , 3 ))/[ {(1 − dı)dı}]

and B() is a Beta

Function.
e.

Author Manuscript

3.
3.6

Generalized residuals (Gourieroux et al. 1987): dı′ ⋅ (d−dı)/{(1 − dı)dı}

Bi-variate probit regression model, which is the MLE for the DGPs.

Results
Descriptive statistics for our DGPs are provided in Table 1. As expected, the true mean
average treatment effect (ATE) parameter values varied across scenarios varying the
intercept in the outcome models, β 0, but not across scenarios varying the intercept in the
treatment models. LATE, however, varies with the intercepts in both the outcome and

Health Econ. Author manuscript; available in PMC 2019 June 26.

Basu et al.

Page 13

Author Manuscript

treatment choice models. As outcomes become rare, following an underlying probit model,
both ATE and LATE decrease.
Simulation results are presented in Tables 2 and 3. Table 2 reports percent bias, the
coefficient of variation, and coverage probabilities on the LATE. We find that 2SLS always
provides consistent estimates of LATE, irrespective of the treatment rarity or outcomes
rarity. This indicates that 2SLS can consistently estimate the LATE effect even if the linear
probability model misfits the data and produces out of range predictions. Results do not
show any major drop in coverage probabilities for LATE across simulation design points.
Estimates from nonlinear 2SRI and bi-variate probit were generally biased for the LATE.
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Table 3 reports percent bias, the coefficient of variation and coverage probabilities on the
ATE. As expected, given the DGPs, bi-variate probit always produced the least biased
estimates of the ATE. Also as expected, 2SLS produced biased estimates of ATE, especially
as the ATE and LATE became increasingly distinct in value with rarer treatment and
outcome. Results showed that all of the 2SRI estimators produced substantially larger biases
(and poor coverage probabilities) than bi-variate probit in estimating ATE. This highlights
the difficulty of estimating the ATE through extrapolation using the first-stage residuals.
Among the residual inclusion approaches, 2SRI with generalized residual appeared to have
the least bias in estimating ATE in most cases. However, the corresponding coverage
probabilities were low.
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One interesting observation was that, for rare outcomes (such as those below 5%), 2SRI with
Anscombe residuals produced the least bias in estimating ATE, with coverage probabilities
close to 95% in each case. The coverage probabilities did not detoriorate when treatment
also became rare. This may indicate that the Anscombe transformation of the first-stage
residuals are helping to better approximate the distribution of ui|vi where the outcomes are
rare and, therefore, abetting the extrapolation for the counterfactuals.
Results for patterns of bias with 2SLS and 2SRI held similar for the simulations with a
sample size of 5000 (Appendix Tables A2 and A3).

4.

EMPIRICAL EXAMPLE

Author Manuscript

To illustrate the potential impact of the estimation method on empirical results, we use the
case of long-term care insurance (LTCI) and its impact on long-term care (LTC) utilization.
This issue has been studied by Konetzka, He, Guo and Nyman (2014) and Coe, Goda and
Van Houtven (2015). This application is fitting to illustrate the concepts examined in the
simulation models, as it is characterized by: 1) a relatively low E(Y) -- few elderly hold
long-term care insurance; 2) an empirically strong and widely accepted instrumental variable
– state tax policies that reduce the cost of insurance influence LTCI holding; and 3) multiple
outcomes, at varying means Pr(Y).
4.1

Data
Three main data sources were used, following Coe, Goda and Van Houtven (2015): (1) the
Health and Retirement Study (HRS) (including RAND versions) (http://
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hrsonline.isr.umich.edu/); (2) the HRS restricted geographic identifiers (HRS/G), in order to
match the individual to the state of residence, and (3) state-level tax subsidy data for the
purchase and holding of state-approved LTCI policies (GS Goda, 2011).
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Data from ten waves of the HRS (1996–2010), a publicly available, bi-annual survey of the
near elderly in the U.S. were used.4 Respondents were ages 50 and older when they initially
entered the sample and many respondents are observed long enough to have used some type
of long-term care. To increase the relevance of the instrumental variable used for analysis –
the state tax subsidy – the sample was limited to individuals who report filing taxes and
individuals in the top half of the income distribution in our sample. The sample size
consisted of 46,639 individual-wave observations. The Cross-Wave Geographic Information
(State) file matches respondents to their state of residence, which is then matched to handcollected data from individual state income tax return forms from 1996–2010 that describe
tax subsidy programs for private long-term care insurance.
4.2

Measures and Descriptive Statistics
Five binary outcome measures were created; the measures had varying means to illustrate
the bias due to the estimation methods. Each outcome measure is created from HRS data one
wave (approximately two years) ahead of the data used to create explanatory measures
described below. Descriptive statistics for the data are shown in Table 3.
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Informal Helper—Defining informal care in the HRS requires an algorithm based on
several variables. The process first identifies whether the person received care for specific
IADLS and ADLS and then uses information from relationship codes measured in the helper
file to determine whether the care was from a child, a friend or another relative to ensure that
the care recipient was not paid. We create 3 variables based on who provided the informal
care: 60 percent of the sample receives informal care from any person; 43 percent receive
informal care from a child; 16.5 percent receive care from other relatives.
Home Health care—The formal home health care variables are: “Since the previous
interview, has any medically-trained person come to your home to help you, yourself?” In
2000, the HRS clarified that medically-trained persons include professional nurses, visiting
nurse’s aides, physical or occupational therapists, chemotherapists, and respiratory oxygen
therapists, which may represent an expansion of the definition of home health care. 6.8
percent received home health care.

Author Manuscript

Nursing home care—The HRS asks: “Since (Previous Wave Interview Month-Year/In
the last two years), have you been a patient overnight in a nursing home, convalescent home,
or other long-term health care facility?” For individuals who died between waves, nursing
home use was measured from data in the HRS exit interviews. 2.3 percent received nursing
home care.

4Earlier waves of the survey are omitted because of the lower quality information on the LTCI question (Finkelstein and McGarry,
2006) and state information is not yet available for later waves.
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LTCI (mean=0.157)—Starting in the 1996 wave, respondents were asked to respond yes or
no to the following question: “Not including government programs, do you now have any
long term care insurance which specifically covers nursing home care for a year or more or
any part of personal or medical care in your home?”. LTCI status is defined as having LTCI
in year t, based on the recorded response to this question; 15.7 percent of individual-waves
had long-term care insurance.
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State Tax Subsidy (an instrument for LTCI)—Following the literature, a binary
variable indicating whether a state has a tax subsidy available in a particular year was
created to be used as an instrument for LCTI. The state tax subsidy indicated any subsidy,
regardless of the form of the subsidy (i.e., credit or a deduction), the fraction of premiums
eligible, monetary caps on the value of the subsidy, income limits, or whether the state
subsidy was available in addition to the federal subsidy (GS Goda, 2011; Konetzka et al.
2014; Coe, Goda and Van Houtven 2015). The availability of a state tax subsidy varied
considerably over time and across states; while only three states had tax incentives for LTCI
in 1996, a total of 24 states plus the District of Columbia had adopted a subsidy by 2008.
Prior literature has provided evidence that the state tax subsidy is empirically important in
whether someone holds an LTCI policy and meets essential criteria for use as an
instrumental variable in this context. In the first stage regression, the estimated coefficient on
the binary state tax subsidy variable suggested that individuals in states with subsidies are
about three percentage points more likely to own LTCI (F-stat: 65.93, p<0.001).
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Individual-level control variables—Control variables in the models included binary
variables indicating respondent’s marital status, sex, number of children, retirement status,
education, income, race, ethnicity, health status (fair or poor self-reported health and the
presence of any limitations in the activities of daily living (ADLs)), and age fixed effects.
Fixed-effects—All models include year and state fixed-effects. The year fixed-effects
account for time trends in the data while the state fixed-effects account for non-time-varying
differences across states. The inclusion of state fixed-effects suggests that the empirical
models identify the effect of LTCI coverage on outcome for individuals whose LTCI
coverage was sensitive to within-state differences in the state tax policy.
Analyses included use of all estimators represented in the simulations models described in
the previous section. Each estimator was used to estimate the effect of long-term care
insurance on each of the five outcomes described above, using the binary state tax subsidy
variable as an instrumental variable. For each estimator, estimates from 500 clustered
bootstrap samples were used to compute standard errors for the marginal effect in each case.
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4.3

Results
The simulation results indicated that 2SLS should produce consistent estimates of LATEs,
regardless of treatment or outcome rarity. Conversely, results suggested 2SRI models were
likely to produce bias in estimating average treatment effects on outcomes (ATE or LATE),
with generalized residuals estimator (2SRI-Gres) producing the least bias. For very rare
outcome, such as nursing home care and home health care in our empirical application, 2SRI
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with Anscombe residual (2SRI-ares) may produce estimates close to the unbiased estimates
of ATE.
Table 4 provides summary statistics for outcomes and other variables used in the empirical
models. The marginal effects and their bootstrapped standard errors are shown in Table 5.

Author Manuscript
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The 2SLS-based consistent LATE estimates for LTCI were −0.302 (Informal care from any
source), −0.329 (Informal care from child), 0.161 (Informal care from relatives), −0.252
(home health care), and 0.087 (Any nursing home care). The interpretation of LATE always
refers to the marginal individuals. For example, in the model predicting informal care from
any source, the LATE estimate suggests that LTCI decreases the use of informal care from
any source by 30 percentage points among people who are moved to acquire LTCI due to the
subsidy. Sometimes, LATE can provide treatment effects estimates that are difficult to
interpret, and may even be considered nonsensical, even when the IV is policy-driven. For
example, assuming that access to LTCI would increase receipt of formal care, which will act
as a substitute for all forms of informal care, the effect of LTCI on Informal care from any
source would perhaps not be expected to be smaller than the effect on Informal care from
child, yet that is what LATE suggests. Similarly, it is difficult to envision how the effect
from having LTCI, for those who have insurance due to state subsidies, increases informal
care from a relative; though this LATE estimate does not reach statistical significance. One
may invoke complicated stories about complementarity between formal care and informal
care from relatives and particularities about the generosity of LTCI for those who have it due
to state subsidies, to explain these result. Then again, the real world is full such complexities
and taking the time to disentangle such nuanced relationships may be considered
worthwhile. Note that the LATEs for different outcomes belong to the same marginal group
of patients who are influenced by this specific IV.
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Treatment effect estimates produced from the 2SRI models are often quite different from the
2SLS-based LATE estimates. This was expected. The 2SRI-Gres estimates of ATE for LTCI
are −0.268 (Informal care from any source), −0.179 (Informal care from child), −0.111
(Informal care from relatives), −0.077 (home health care) and 0.023 (Any nursing home
care). Taken at face value, these estimates did not have the contextual inconsistencies, as it
relates to our a priori theory about the relationships under study, that were seen in LATE
estimates. The 2SRI estimates were also quite similar to those produced by the Bi-Probit
model, especially when outcomes mean was close to 0.50. It is quite plausible that the
underlying distribution of outcomes is well approximated by a normal distribution when the
binary outcome mean is close to 0.50, and hence, for these outcomes, the bi-probit model is
likely to produce consistent estimates of ATE.5 For rarer outcomes, the bi-probit estimates
and the 2SRI-gres estimates differ and it is not clear if any of those estimates are unbiased
estimates of ATE.
For any nursing home care, which is the rarest outcome, 2SRI-ares (with Anscombe
residuals) estimates of ATE are close to being unbiased, according to our simulations.
5Note that in contrast to our simulations, where we generate all outcomes under the normal distribution and found the BVP perform
better for rare outcomes, here we are suggesting that when the outcomes mean is around 50% its underlying data-generating process is
more likely to be normal.
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Although this point estimate of 0.038 differs from that of Bi-probit (= 0.023), neither reach
statistical significance. Hence, it is reasonable to conclude that the overall average effect of
LTCI in the entire population does not significantly affect any nursing home care.

5.

CONCLUSIONS
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The economics literature is teeming with applications where linear probability models are
used for binary outcomes. In case of instrumental variables methods, both the binary
treatment (in 1st stage) and the binary outcome (in 2nd stage) are often modeled with linear
probability models with two-stage least squares (2SLS) estimators. In contrast, a control
function approach may be used with non-linear models (e.g. probit or logit applied to first
and/or second stage models) where the estimated residuals from the first stage are used as an
additional covariate in the second stage. However, the residual inclusion approach does not
identify a treatment effect non-parametrically. Instead, it relies on extrapolation for the
counterfactual outcomes conditional of the level of a residual using the functional form used.
The proper characterization of these residuals is thought to be important to carry out such
extrapolations. This research considered the case where a local average treatment effect
(LATE) parameter is non-parametrically identified using a binary instrument in the presence
of all binary covariates. Extensive simulations that varied the rarity of both the outcome and
treatment were performed to answer questions of whether 2SLS or 2SRI methods with
different forms of residuals has the least bias in estimating the LATE or the ATE parameters.
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Results show that the 2SLS method with binary IV, applied to a binary endogenous
treatment and a binary outcome, produces consistent estimates of LATE across the entire
range of rarity for either treatment or the outcome. The rarity of either does not affect the
coverage probabilities of these estimators. In contrast, the 2SRI approach with any residuals
studied was a biased estimator for LATE. However, in principle, the 2SRI estimators are
designed to estimate the ATE parameter. Yet, still, results showed that 2SRI does not appear
dependable for producing unbiased estimates of ATE. Rather, there were varying levels of
bias associated with 2SRI estimates of ATE. Among the residual forms, 2SRI with
generalized residuals appeared to produce the least biased estimates of the ATE. For very
rare outcomes (<5%) 2SRI with Anscombe residual generated the least bias in estimating
ATE. We conjecture that the symmetric transformation of these residuals may be leading to
better extrapolation properties of the 2SRI estimators. However, whether these findings
represent a general operating characteristic of 2SRI or are unique to our simulation settings
is not known.
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Results from this study conform with the simulation results of Chapman and Brooks (2016),
who compared 2SLS and nonlinear 2SRI with raw residuals in simulation models with
binary treatment, binary outcome, and continuous instruments to find that 2SLS produced
consistent estimates for the IV effect while 2SRI did not reliably estimate either the ATE or
the IV effect. However, their study did not examine models with binary instruments, vary
rarity of treatment or outcome from approximately 0.5, examine alternative forms of 2SRI
residuals, or report coverage probabilities of estimates. The results of this study provide
additional and more comprehensive evidence showing how 2SLS are consistent estimators
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of LATE over a wide range of scenarios varying by rarity of binary outcomes and binary
treatments.

Author Manuscript

We hope that this work will help the applied researcher to cautiously approach and interpret
the results generated from IV estimation in models with binary treatment, binary outcome
and binary instrumental variable. Careful interpretation of treatment effects that are
identified and being estimated, as well as the potential for bias arising from methodologic
decisions, are key factors to consider in conducting these analyses and responsibly reporting
the results from them. While estimating the LATE may be straightforward given a valid
instrument, the interpretation of LATEs is often nuanced and may heighten the potential for
unintentionally misleading or erroneous inferences and conclusions. On the other hand,
interpreting population mean treatment effect parameters such as the ATE is straight-forward
but estimating them is often problematic and potentially infeasible, as doing so demands
either richer data or a slew of statistical assumptions that may not be met. Moreover, under
settings of essential heterogeneity in treatment effectiveness, the potential usefulness of a
population wide average effect may be limited and more nuanced parameters are required
for practical impact. It’s important that researchers understand precisely the assumptions
underlying identification of alternative treatment effect concepts and the related theory to
support an approach for estimating them. We are hopeful that our results and discussions can
help untangle these challenges.
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Appendix
Table A1:

Simulations results (N=5,000) for Local Average Treatment Effects (LATEs) - %Bias
(Coeff. Var.) {Coverage Pr}
E(Y)

Estimators

Pr(D) = 0.55

Pr(D) = 0.70

Pr(D) = 0.85

Pr(D) = 0.93

Pr(D) = 0.995

0.50~0.60

Naïve Probit

170 [.02] {0}

182 [.03] {0}

242 [.03] {0}

381 [.03] {0}

845 [.04] {0}

2SLS

−1 [.27] {.94}

−2 [.35] {.95}

−4 [.71] {.96}

−11 [2.08] {.96}

−61 [27.76] {.97}

2SRI

−47 [.59] {.67}

−31 [.5] {.83}

44 [.37] {.86}

208 [.35] {.45}

476 [.85] {.58}
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0.80 ~0.90

2SRI - sres

11 [.27] {.92}

32 [.29] {.82}

96 [.33] {.59}

215 [.42] {.52}

428 [.99] {.53}

2SRI - dres

−103 [−9.25] {.14}

−99 [38.24] {.28}

−47 [1.25] {.82}

131 [.58] {.76}

534 [.75] {.5}

2SRI - ares

−88 [2.74] {.24}

−81 [1.98] {.41}

−32 [.94] {.86}

123 [.59] {.79}

488 [.81] {.54}

2SRI - gres

−46 [.56] {.65}

−32 [.49] {.82}

24 [.44] {.91}

155 [.46] {.67}

399 [.98] {.61}

Bi.Probit

−22 [.31] {.83}

−16 [.34] {.89}

9 [.49] {.93}

54 [1.06] {.87}

297 [1.83] {.47}

Naïve Probit

233 [.04] {0}

185 [.04] {0}

155 [.04] {0}

160 [.04] {0}

226 [.06] {0}

2SLS

−3 [.52] {.95}

−1 [.37] {.95}

−1 [.36] {.94}

−2 [.53] {.95}

−7 [1.74] {.96}

2SRI

−3 [.47] {.95}

−36 [.54] {.75}

−70 [1.01] {.33}

−78 [1.71] {.42}

−44 [1.71] {.79}
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E(Y)

0.9 ~ 0.95

Author Manuscript

0.95~0.98

Estimators

Pr(D) = 0.55

Pr(D) = 0.70

Pr(D) = 0.85

Pr(D) = 0.93

Pr(D) = 0.995

2SRI - sres

74 [.19] {.39}

69 [.17] {.32}

57 [.18] {.41}

61 [.22] {.52}

106 [.34] {.55}

2SRI - dres

−75 [2.27] {.73}

−95 [7.59] {.26}

−103 [−9.52] {.09}

−94 [5.58] {.22}

−33 [1.26] {.82}

2SRI - ares

−52 [1.07] {.83}

−68 [1.09] {.49}

−76 [1.15] {.23}

−70 [1.18] {.44}

−18 [1.02] {.84}

2SRI - gres

−4 [.45] {.96}

−31 [.47] {.8}

−51 [.58] {.5}

−59 [.87] {.51}

−38 [1.35] {.79}

Bi.Probit

−5 [.4] {.94}

−31 [.4] {.74}

−47 [.45] {.43}

−52 [.62] {.47}

−33 [1.11] {.8}

Naïve Probit

322 [.05] {0}

232 [.05] {0}

165 [.05] {0}

143 [.06] {0}

160 [.08] {0}

2SLS

−2 [.96] {.93}

0 [.61] {.93}

1 [.46] {.93}

0 [.52] {.93}

−5 [1.15] {.95}

2SRI

58 [.44] {.82}

−9 [.54] {.92}

−69 [1.18] {.41}

−94 [4.73] {.22}

−83 [3.52] {.53}

2SRI - sres

134 [.19] {.15}

97 [.19] {.19}

64 [.2] {.43}

43 [.21] {.66}

51 [.29] {.77}

2SRI - dres

−27 [1.35] {.94}

−77 [2.57] {.69}

−97 [10.3] {.19}

−98 [12.3] {.14}

−77 [2.09] {.51}

2SRI - ares

0 [.86] {.94}

−45 [.96] {.83}

−66 [.98] {.4}

−72 [1.08] {.34}

−55 [1.13] {.64}

2SRI - gres

52 [.43] {.81}

−8 [.51] {.91}

−47 [.63] {.57}

−66 [.9] {.34}

−67 [1.47] {.57}

Bi.Probit

24 [.54] {.92}

−21 [.51] {.88}

−50 [.57] {.45}

−62 [.71] {.29}

−60 [1.09] {.55}

Naïve Probit

492 [.07] {0}

322 [.07] {0}

202 [.08] {0}

150 [.09] {0}

130 [.12] {0}

2SLS

−3 [2] {.94}

−4 [1.1] {.94}

−2 [.66] {.94}

0 [.58] {.95}

−1 [.9] {.95}

2SRI

158 [.47] {.83}

34 [.53] {.99}

−61 [1.22] {.64}

−101 [−37.55] {.25}

−92 [6.21] {.51}

2SRI - sres

236 [.29] {.32}

144 [.21] {.17}

84 [.24] {.56}

41 [.26] {.81}

19 [.34] {.92}

2SRI - dres

56 [1.15] {.95}

−52 [2.02] {.98}

−92 [5.92] {.45}

−98 [15.37] {.19}

−87 [2.92] {.41}

Author Manuscript

2SRI - ares

86 [.82] {.95}

−14 [.91] {1}

−55 [.96] {.64}

−70 [.98] {.39}

−65 [1.27] {.53}

2SRI - gres

148 [.47] {.81}

25 [.52] {.99}

−38 [.7] {.73}

−67 [.89] {.43}

−74 [1.64] {.48}

Bi.Probit

26 [2.05] {.85}

−7 [.78] {.97}

−50 [.73] {.64}

−68 [.74] {.34}

−70 [1.25] {.46}

2SRI – sres: 2SRI with standardized residuals; 2SRI – dres: 2SRI with deviance residuals; 2SRI – ares: 2SRI with
Anscombe residuals; 2SRI-gres: 2SRI with generalized residuals

Table A2:

Simulations results (N=5,000) comparing to Average Treatment Effects (ATEs) - %Bias
(Coeff. Var.) {Coverage Pr}

Author Manuscript

E(Y)

Estimators

0.50~0.60

Naïve Probit

248 [.02] {0}

237 [.03] {0}

210 [.03] {0}

187 [.03] {0}

163 [.04] {0}

2SLS

28 [.27] {.88}

18 [.35] {.91}

−13 [.71] {.94}

−47 [2.08] {.94}

−89 [27.76] {.96}

2SRI

−32 [.59] {.86}

−17 [.5] {.9}

31 [.37] {.89}

84 [.35] {.66}

61 [.85] {.71}

2SRI - sres

44 [.27] {.81}

58 [.29] {.68}

78 [.33] {.64}

88 [.42] {.68}

47 [.99] {.67}

2SRI - dres

−104 [−9.25] {.3}

−99 [38.24] {.39}

−52 [1.25] {.8}

38 [.58] {.85}

77 [.75] {.69}

2SRI - ares

−85 [2.74] {.42}

−78 [1.98] {.53}

−38 [.94] {.84}

33 [.59] {.86}

64 [.81] {.69}

2SRI - gres

−31 [.56] {.86}

−18 [.49] {.90}

12 [.44] {.91}

52 [.46] {.81}

39 [.98] {.7}

Bi.Probit

1 [.31] {.93}

0 [.34] {.93}

−1 [.49] {.93}

−8 [1.06] {.86}

11 [1.83] {.5}

Naïve Probit

244 [.04] {0}

314 [.04] {0}

407 [.04] {0}

488 [.04] {0}

582 [.06] {0}

2SLS

0 [.52] {.95}

43 [.37] {.84}

97 [.36] {.71}

121 [.53] {.82}

95 [1.74] {.93}

0.80 ~0.90

Pr(D) = 0.55

Pr(D) = 0.70

Pr(D) = 0.85
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Pr(D) = 0.995
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E(Y)

0.9 ~ 0.95

Author Manuscript

0.95~0.98

Estimators

Pr(D) = 0.55

Pr(D) = 0.70

Pr(D) = 0.85

Pr(D) = 0.93

Pr(D) = 0.995

2SRI

0 [.47] {.95}

−7 [.54] {.95}

−40 [1.01] {.81}

−49 [1.71] {.77}

17 [1.71] {.9}

2SRI - sres

79 [.19] {.36}

145 [.17] {.07}

213 [.18] {.02}

262 [.22] {.07}

331 [.34] {.31}

2SRI - dres

−74 [2.27] {.74}

−93 [7.59] {.53}

−105 [−9.52] {.39}

−87 [5.58] {.59}

40 [1.26] {.89}

2SRI - ares

−50 [1.07] {.83}

−53 [1.09] {.78}

−51 [1.15] {.75}

−32 [1.18] {.81}

71 [1.02] {.89}

2SRI - gres

−1 [.45] {.97}

1 [.47] {.94}

−3 [.58] {.92}

−8 [.87] {.88}

29 [1.35] {.88}

Bi.Probit

−2 [.4] {.94}

0 [.4] {.95}

4 [.45] {.95}

9 [.62] {.91}

41 [1.11] {.9}

Naïve Probit

226 [.05] {0}

327 [.05] {0}

482 [.05] {0}

648 [.06] {0}

883 [.08] {0}

2SLS

−25 [.96] {.91}

28 [.61] {.91}

121 [.46] {.68}

208 [.52] {.65}

260 [1.15] {.85}

2SRI

22 [.44] {.9}

18 [.54] {.94}

−32 [1.18] {.84}

−80 [4.73] {.64}

−37 [3.52] {.86}

2SRI - sres

81 [.19] {.3}

154 [.19] {.05}

260 [.2] {0}

340 [.21] {.02}

472 [.29] {.19}

2SRI - dres

−44 [1.35] {.93}

−70 [2.57] {.81}

−93 [10.3] {.59}

−93 [12.3] {.57}

−13 [2.09] {.85}

2SRI - ares

−23 [.86] {.93}

−29 [.96] {.91}

−25 [.98] {.87}

−14 [1.08] {.86}

71 [1.13] {.93}

2SRI - gres

18 [.43] {.92}

18 [.51] {.94}

17 [.63] {.91}

3 [.9] {.9}

27 [1.47] {.9}

Bi.Probit

−4 [.54] {.95}

2 [.51] {.94}

10 [.57] {.93}

16 [.71] {.91}

52 [1.09] {.93}

Author Manuscript

Naïve Probit

202 [.07] {0}

326 [.07] {0}

546 [.08] {0}

815 [.09] {0}

1277 [.12] {0}

2SLS

−50 [2] {.89}

−3 [1.1] {.94}

110 [.66] {.86}

265 [.58] {.7}

491 [.9] {.79}

2SRI

32 [.47] {.96}

35 [.53] {.99}

−16 [1.22] {.95}

−103 [−37.55] {.71}

−50 [6.21] {.79}

2SRI - sres

72 [.29] {.79}

146 [.21] {.17}

295 [.24] {.03}

417 [.26] {.03}

612 [.34] {.24}

2SRI - dres

−20 [1.15] {.96}

−52 [2.02] {.98}

−83 [5.92] {.8}

−94 [15.37] {.71}

−25 [2.92] {.83}

2SRI - ares

−5 [.82] {.96}

−14 [.91] {1}

−4 [.96] {.96}

10 [.98] {.93}

109 [1.27] {.93}

27 [.47] {.95}

26 [.52] {.99}

32 [.7] {.98}

21 [.89] {.94}

55 [1.64] {.91}

−36 [2.05] {.94}

−6 [.78] {.97}

7 [.73] {.94}

18 [.74] {.93}

78 [1.25] {.93}

2SRI - gres
Bi.Probit

2SRI – sres: 2SRI with standardized residuals; 2SRI – dres: 2SRI with deviance residuals; 2SRI – ares: 2SRI with
Anscombe residuals; 2SRI-gres: 2SRI with generalized residuals

Table A3:

Simulations results (N=50,000) for Average Treatment Effects (LATEs) with logit Data
generating Process - %Bias (Coeff. Var.) {Coverage Pr}
E(Y)
0.50~0.60

Author Manuscript

0.80 ~0.90

0.9 ~ 0.95

Estimators

Pr(D) = 0.55

Pr(D) = 0.70

Pr(D) = 0.85

Pr(D) = 0.93

Pr(D) = 0.995

2SRI

−13 [.23] {.84}

−5 [.21] {.91}

11 [.2] {.89}

24 [.21] {.82}

35 [.3] {.84}

2SRI - ares

−46 [.42] {.38}

−30 [.33] {.72}

4 [.23] {.91}

40 [.19] {.69}

82 [.19] {.37}

2SRI - gres

−13 [.23] {.81}

−5 [.21] {.91}

11 [.2] {.91}

24 [.21] {.83}

35 [.3] {.84}

2SRI

2 [.2] {.9}

−11 [.25] {.88}

−28 [.35] {.76}

−42 [.54] {.7}

−60 [1.26] {.68}

2SRI - ares

−32 [.37] {.62}

−39 [.4] {.54}

−26 [.34] {.75}

−2 [.29] {.93}

40 [.3] {.86}

2SRI - gres

2 [.2] {.85}

−11 [.25] {.83}

−28 [.35] {.74}

−42 [.54] {.7}

−60 [1.26] {.68}

2SRI

13 [.2] {.85}

0 [.23] {.92}

−25 [.36] {.8}

−52 [.68] {.65}

−82 [2.68] {.57}

2SRI - ares

−19 [.34] {.82}

−29 [.37] {.71}

−25 [.36] {.79}

−8 [.32] {.9}

30 [.35] {.93}

2SRI - gres

13 [.2] {.74}

0 [.23] {.88}

−25 [.36] {.78}

−52 [.68] {.64}

−82 [2.68] {.57}
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E(Y)
0.95~0.98

Estimators

Pr(D) = 0.55

Pr(D) = 0.70

Pr(D) = 0.85

Pr(D) = 0.93

Pr(D) = 0.995

2SRI

22 [.19] {.78}

11 [.23] {.9}

−16 [.37] {.87}

−52 [.84] {.65}

−94 [9.6] {.53}

2SRI - ares

−9 [.32] {.88}

−18 [.36] {.84}

−18 [.38] {.84}

−6 [.37] {.9}

26 [.41] {.96}

2SRI - gres

22 [.19] {.66}

11 [.23] {.85}

−16 [.37] {.86}

−52 [.84] {.67}

−94 [9.6] {.53}

2SRI – ares: 2SRI with Anscombe residuals; 2SRI-gres: 2SRI with generalized residuals

Table A4:

Simulations results (N=50,000) for Average Treatment Effects (LATEs) with cloglog Data
generating Process - %Bias (Coeff. Var.) {Coverage Pr}
E(Y)
0.50~0.60

Author Manuscript

0.80 ~0.90

0.9 ~ 0.95

0.95~0.98

Estimators

Pr(D) = 0.55

Pr(D) = 0.70

2SRI

−25 [.23] {.64}

−18 [.21] {.78}

−4 [.2] {.92}

7 [.21] {.93}

16 [.31] {.9}

2SRI - ares

−54 [.43] {.19}

−40 [.33] {.44}

−10 [.23] {.91}

21 [.19] {.85}

59 [.19] {.51}

2SRI - gres

27 [.09] {.68}

35 [.1] {.45}

83 [.1] {0}

162 [.09] {0}

250 [.07] {.01}

2SRI

Pr(D) = 0.85

Pr(D) = 0.93

Pr(D) = 0.995

1 [.2] {.93}

−11 [.24] {.9}

−28 [.34] {.76}

−42 [.53] {.7}

−59 [1.19] {.68}

2SRI - ares

−32 [.35] {.69}

−38 [.38] {.58}

−26 [.33] {.77}

−1 [.29] {.93}

41 [.3] {.85}

2SRI - gres

33 [.08] {.67}

37 [.1] {.61}

39 [.15] {.6}

57 [.25] {.63}

174 [.47] {.65}

2SRI

27 [.19] {.74}

12 [.23] {.91}

−15 [.36] {.88}

−45 [.68] {.72}

−77 [2.47] {.63}

2SRI - ares

−9 [.33] {.9}

−20 [.37] {.85}

−14 [.36] {.88}

6 [.33] {.93}

48 [.34] {.88}

2SRI - gres

26 [.08] {.95}

36 [.11] {.79}

43 [.16] {.69}

48 [.26] {.77}

109 [.66] {.88}

2SRI

64 [.19] {.43}

49 [.23] {.68}

14 [.37] {.94}

−33 [.81] {.85}

−89 [7.68] {.67}

2SRI - ares

−13 [.31] {.97}

10 [.36] {.92}

11 [.38] {.93}

27 [.37] {.94}

70 [.4] {.93}

2SRI - gres

14 [.1] {1}

26 [.12] {.98}

41 [.18] {.84}

45 [.27] {.86}

101 [.73] {.94}

Author Manuscript

2SRI – ares: 2SRI with Anscombe residuals; 2SRI-gres: 2SRI with generalized residuals
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Figure 1:

Illustration of residual inclusion approach for binary treatment variable.
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LATE = 0.150

TT= 0.176
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TT= 0.168

Pr(D) = 0.85

Pr(D) = 0.70

−0.3

E(Y) = 0.51

−1.25

Pr(D) = 0.55

−2

Exposure DGP (α0)

LATE = 0.107

TUT =0.144

TT=0.020

ATE = 0.029

E(Y) = 0.98

Pr(D) = 0.93

LATE = 0.178

TUT =0.197

TT=0.047

ATE = 0.058

E(Y) = 0.95

Pr(D) = 0.93

LATE = 0.218

TUT =0.201

TT= 0.088

ATE = 0.097

E(Y) = 0.87

Pr(D) = 0.93

LATE = 0.098

TUT =0.071

TT= 0.172

ATE = 0.165

E(Y) = 0.57

Pr(D) = 0.93

0.5

LATE = 0.175

TUT =0.185

TT=0.023

ATE = 0.029

E(Y) = 0.98

Pr(D) = 0.995

LATE =0.220

TUT =0.217

TT=0.054

ATE = 0.058

E(Y) = 0.95

Pr(D) = 0.995

LATE = 0.203

TUT =0.172

TT=0.93

ATE = 0.097

E(Y) = 0.89

Pr(D) = 0.995

LATE = 0.046

TUT =0.031

TT= 0.170

ATE = 0.165

E(Y) = 0.58

Pr(D) = 0.995

1.5

TT: Effect on the Treated; TUT: Effect on the Untreated; True values of TT and TUT are provided for information only

2.5

1.5

0.5

−2

Outcomes DGP (β0)
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Descriptive statistics for alternative data generating processes.
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0.95~0.98

0.9 ~ 0.95

0.80 ~0.90

493 [.02] {0}
−2 [.6] {.95}
174 [.1] {0}

2SLS

2SRI

29 [.16] {.66}

Bi.Probit

Naïve Probit

7 [.23] {.91}
56 [.12] {.14}

2SRI - gres

2SRI - dres

2SRI - ares

134 [.06] {0}
−18 [.34] {.9}

2SRI - sres

61 [.12] {.1}

−3 [.13] {.93}

Bi.Probit

−1 [.29] {.94}

−1 [.15] {.92}

2SRI - gres

2SRI

−48 [.34] {.15}

2SRI - ares

2SLS

−71 [.69] {.04}

2SRI - dres

322 [.02] {0}

75 [.06] {0}

Naïve Probit

−1 [.16] {.92}

2SRI - sres

Bi.Probit

2SRI

2SRI - gres

0 [.17] {.91}

−48 [.18] {0}
−23 [.1] {.17}

2SRI - ares

233 [.01] {0}

−91 [1.07] {0}

2SRI - dres

2SLS

−106 [−1.45] {0}

2SRI - sres

Naïve Probit

−49 [.19] {0}
12 [.08] {.75}

2SRI

170 [.01] {0}
−1 [.08] {.96}

2SLS

0.50~0.60

Pr(D) = 0.55

Naïve Probit

Estimators

E(Y)

32 [.14] {.62}

−1 [.32] {.96}

324 [.02] {0}

−22 [.15] {.48}

−11 [.15] {.83}

−47 [.28] {.11}

−78 [.77] {.01}

97 [.05] {0}

−12 [.16] {.82}

−1 [.18] {.95}

232 [.02] {0}

−31 [.14] {.08}

−31 [.17] {.17}

−68 [.39] {0}

−97 [3.72] {0}

71 [.05] {0}

−38 [.19] {.09}

0 [.13] {.92}

185 [.01] {0}

−17 [.1] {.5}

−33 [.15] {.13}

−84 [.68] {0}

−102 [−5.19] {0}

36 [.09] {.17}

−33 [.16] {.17}

−1 [.1] {.96}

182 [.01] {0}

Pr(D) = 0.70

−67 [.36] {0}

−1 [.19] {.97}

203 [.02] {0}

−54 [.17] {0}

−52 [.19] {0}

−71 [.32] {0}

−103 [−2.91] {0}

68 [.06] {0}

−76 [.41] {0}

−1 [.13] {.95}

166 [.02] {0}

−50 [.15] {0}

−55 [.2] {0}

−79 [.42] {0}

−107 [−1.15] {0}

63 [.06] {0}

−75 [.38] {0}

0 [.12] {.92}

156 [.01] {0}

9 [.15] {.92}

22 [.14] {.73}

−34 [.3] {.62}

−50 [.42] {.36}

109 [.11] {0}

42 [.12] {.34}

−2 [.21] {.95}

242 [.01] {0}

Pr(D) = 0.85

−108 [−.99] {0}

−2 [.17] {.97}

151 [.03] {0}

−67 [.2] {0}

−73 [.31] {0}

−78 [.39] {0}

−105 [−1.29] {0}

51 [.08] {0}

−102 [−3.35] {0}

−1 [.15] {.94}

144 [.02] {0}

−56 [.19] {0}

−65 [.3] {0}

−74 [.42] {0}

−101 [−6.45] {0}

72 [.08] {0}

−86 [.8] {0}

0 [.17] {.93}

161 [.01] {0}

63 [.3] {.75}

150 [.15] {.03}

120 [.19] {.18}

126 [.19] {.15}

267 [.14] {0}

205 [.12] {0}

−5 [.59] {.94}

382 [.01] {0}

Pr(D) = 0.93

−111 [−.33] {0}

−3 [.25] {.96}

133 [.04] {0}

−73 [.38] {0}

−84 [.8] {0}

−68 [.49] {.04}

−96 [2.73] {0}

63 [.11] {.02}

−108 [−1.19] {0}

−2 [.31] {.96}

162 [.02] {0}

−51 [.44] {.33}

−62 [.69] {.35}

−35 [.45] {.67}

−59 [.65] {.38}

134 [.11] {0}

−79 [1.38] {.25}

−1 [.51] {.93}

228 [.02] {0}

171 [1.57] {.84}

656 [.22] {.05}

775 [.15] {0}

834 [.12] {0}

799 [.2] {.04}

774 [.15] {.01}

−30 [4.64] {.94}

846 [.01] {0}

Pr(D) = 0.995

Simulations results (N=50,000) for Local Average Treatment Effects (LATEs) - %Bias (Coeff. Var.) {Coverage Pr}

Author Manuscript
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Author Manuscript
111 [.17] {.16}
164 [.1] {0}
90 [.24] {.48}

2SRI - dres

2SRI - ares

2SRI - gres

Bi.Probit

142 [.06] {0}

−2 [.19] {.96}

25 [.14] {.72}

−11 [.23] {.94}

−43 [.44] {.63}

−53 [.2] {0}

−44 [.21] {.05}

−60 [.29] {0}

−95 [2.42] {0}

87 [.07] {0}

Pr(D) = 0.85

−73 [.22] {0}

−74 [.3] {0}

−76 [.32] {0}

−104 [−1.66] {0}

48 [.09] {.01}

Pr(D) = 0.93

−83 [.4] {0}

−89 [.82] {0}

−78 [.49] {0}

−102 [−2.92] {0}

30 [.12] {.4}

Pr(D) = 0.995

2SRI – sres: 2SRI with standardized residuals; 2SRI – dres: 2SRI with deviance residuals; 2SRI – ares: 2SRI with Anscombe residuals; 2SRI-gres: 2SRI with generalized residuals; Shaded cells highlight
estimator with lowest percentage bias.

244 [.06] {0}
88 [.22] {.45}

2SRI - sres

Pr(D) = 0.70

Author Manuscript
Pr(D) = 0.55

Author Manuscript

Estimators

Author Manuscript

E(Y)
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0.95~0.98

0.9 ~ 0.95

0.80 ~0.90

−88 [1.07] {0}
−33 [.18] {.3}
−1 [.1] {.95}

2SRI - ares

2SRI - gres

Bi.Probit

−50 [.6] {.62}
40 [.1] {.23}

Bi.Probit

2SRI

0 [.16] {.92}

2SRI - gres

2SLS

21 [.12] {.67}

2SRI - ares

203 [.02] {0}

−18 [.23] {.85}

2SRI - dres

Naïve Probit

81 [.06] {0}
−37 [.34] {.6}

2SRI - sres

24 [.12] {.6}

Bi.Probit

−24 [.29] {.79}

0 [.13] {.94}

2SRI - gres

2SRI

2 [.15] {.92}

2SRI - ares

2SLS

−47 [.34] {.22}

2SRI - dres

226 [.02] {0}

−71 [.69] {.04}

2SRI - sres

Naïve Probit

2 [.16] {.9}
80 [.06] {0}

2SRI

3 [.17] {.9}

−108 [−1.45] {0}

2SRI - dres

244 [.01] {0}

44 [.08] {.05}

2SRI - sres

2SLS

−34 [.19] {.28}

2SRI

Naïve Probit

248 [.01] {0}
28 [.08] {.28}

2SLS

0.50~0.60

Pr(D) = 0.55

Naïve Probit

Estimators

E(Y)

33 [.14] {.60}

0 [.32] {.96}

328 [.02] {0}

0 [.15] {.95}

14 [.15] {.85}

−31 [.28] {.59}

−72 [.77] {.09}

154 [.05] {0}

13 [.16] {.89}

27 [.18] {.76}

327 [.02] {0}

0 [.14] {.91}

0 [.17] {.91}

−54 [.39] {.1}

−95 [3.72] {0}

149 [.05] {0}

−10 [.19] {.85}

45 [.13] {.25}

314 [.01] {0}

−1 [.1] {.97}

−20 [.15] {.63}

−80 [.68] {0}

−103 [−5.19] {0}

63 [.09] {.01}

−20 [.16] {.66}

18 [.1] {.69}

237 [.01] {0}

Pr(D) = 0.70

−29 [.36] {.78}

111 [.19] {.26}

549 [.02] {0}

0 [.17] {.94}

4 [.19] {.95}

−37 [.32] {.5}

−107 [−2.91] {0}

268 [.06] {0}

−48 [.41] {.36}

117 [.13] {.02}

484 [.02] {0}

0 [.15] {.93}

−10 [.2] {.89}

−58 [.42] {.1}

−114 [−1.15] {0}

224 [.06] {0}

−49 [.38] {.25}

98 [.12] {.01}

407 [.01] {0}

−1 [.15] {.95}

11 [.14] {.88}

−40 [.3] {.42}

−55 [.42] {.19}

90 [.11] {0}

28 [.12] {.55}

−11 [.21] {.92}

211 [.01] {0}

Pr(D) = 0.85

−128 [−.99] {.03}

259 [.17] {.02}

819 [.03] {0}

1 [.2] {.95}

−17 [.31] {.83}

−32 [.39] {.7}

−115 [−1.29] {0}

365 [.08] {0}

−107 [−3.35] {.04}

204 [.15] {0}

649 [.02] {0}

0 [.19] {.94}

−20 [.3] {.8}

−42 [.42] {.56}

−103 [−6.45] {.01}

289 [.08] {0}

−68 [.8] {.26}

125 [.17] {.1}

489 [.01] {0}

−3 [.3] {.94}

49 [.15] {.42}

31 [.19] {.74}

35 [.19] {.71}

119 [.14] {.02}

82 [.12] {.03}

−43 [.59] {.78}

187 [.01] {0}

Pr(D) = 0.93

−164 [−.33] {.06}

482 [.25] {.13}

1292 [.04] {0}

1 [.38] {.93}

−39 [.8] {.76}

19 [.49] {.95}

−85 [2.73] {.42}

519 [.11] {0}

−131 [−1.19] {.19}

272 [.31] {.38}

891 [.02] {0}

2 [.44] {.93}

−20 [.69] {.87}

36 [.45] {.88}

−13 [.65] {.89}

390 [.11] {0}

−55 [1.38] {.72}

107 [.51] {.78}

587 [.02] {0}

−25 [1.57] {.85}

111 [.22] {.36}

144 [.15] {.05}

161 [.12] {.01}

151 [.2] {.18}

144 [.15] {.09}

−80 [4.64] {.86}

164 [.01] {0}

Pr(D) = 0.995

Simulations results (N=50,000) comparing to Average Treatment Effects (ATEs) - %Bias (Coeff. Var.) {Coverage Pr}

Author Manuscript
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Author Manuscript
8 [.17] {.91}
35 [.1] {.32}
−3 [.24] {.94}

2SRI - dres

2SRI - ares

2SRI - gres

Bi.Probit

144 [.06] {0}

−1 [.19] {.96}

26 [.14] {.7}

−10 [.23] {.94}

−42 [.44] {.66}

0 [.2] {.96}

19 [.21] {.91}

−15 [.29] {.89}

−89 [2.42] {.1}

301 [.07] {0}

Pr(D) = 0.85

0 [.22] {.97}

−3 [.3] {.95}

−12 [.32] {.91}

−114 [−1.66] {.02}

444 [.09] {0}

Pr(D) = 0.93

2 [.4] {.94}

−36 [.82] {.8}

30 [.49] {.97}

−112 [−2.92] {.21}

679 [.12] {0}

Pr(D) = 0.995

2SRI – sres: 2SRI with standardized residuals; 2SRI – dres: 2SRI with deviance residuals; 2SRI – ares: 2SRI with Anscombe residuals; 2SRI-gres: 2SRI with generalized residuals; Shaded cells highlight
estimator with lowest percentage bias.

76 [.06] {0}
−4 [.22] {.96}

2SRI - sres

Pr(D) = 0.70

Author Manuscript
Pr(D) = 0.55

Author Manuscript

Estimators

Author Manuscript

E(Y)
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Table 4:

Author Manuscript

Descriptive Statistics for HRS dataset
Binary Variables

Mean (sd)

Outcomes
Informal Care from Any Source

0.60 (0.49)

Informal Care from Child

0.43 (0.50)

Informal Care from other Relative

0.165 (0.37)

Home Health Care

0.068 ( 0.25)

Any Nursing Home Care

0.023 (0.15)

Treatment
LTCI coverage

0.157 (0.364)

IV
Subsidies

0.335 (0.472)

Author Manuscript

Other covariates

Author Manuscript

Marital status==2

0.11 (0.32)

Marital status ==3

0.17 (0.37)

Marital status==4

0.06 (0.24)

Female

0.56 (0.5)

No. of children==1

0.1 (0.3)

No. of children==2

0.31 (0.46)

No. of children==3

0.22 (0.42)

No. of children==4

0.13 (0.34)

No. of children==5

0.15 (0.36)

No. of children==6

0.01 (0.11)

Retired

0.47 (0.5)

Education category ==2

0.35 (0.48)

Education category ==3

0.26 (0.44)

Education category ==4

0.3 (0.46)

Income category==2

0.36 (0.48)

Income category==3

0.64 (0.48)

Race category ==2

0.06 (0.25)

Race category ==3

0.03 (0.18)

Fair/Poor health

0.17 (0.37)

Any ADL

0.1 (0.29)

Author Manuscript
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Author Manuscript

Author Manuscript
−0.032 (0.006)++
−0.329 (0.165)++
−0.238 (0.099)++
−0.074 (0.029)++
−0.28 (0.082)++
−0.198 (0.068)++
−0.179 (0.061)++
−0.179 (0.059)++

−0.037 (0.006)++
−0.302 (0.165)+
−0.319 (0.103)++
−0.118 (0.029)++
−0.392 (0.085)++
−0.297 (0.07)++
−0.268 (0.062)++
−0.283 (0.055)++

Naïve Probit

2SLS

2SRI

2SRI - sres

2SRI - dres

2SRI - ares

2SRI – gres

Bi.Probit

−0.147 (0.044)++

−0.111 (0.032)++

−0.114 (0.038)++

−0.126 (0.052)++

−0.06 (0.017)++

−0.091 (0.062)

0.161 (0.114)

−0.015 (0.004)++

Pr(Y) = 0.165

Informal Care from other Relative

−0.117 (0.033)++

−0.077 (0.023)++

−0.085 (0.026)++

−0.127 (0.032)++

−0.028 (0.013)++

−0.142 (0.031)++

−0.252 (0.089)++

−0.005 (0.003)

Pr(Y) = 0.07

Home Health Care

0.023 (0.028)

0.029 (0.041)

0.038 (0.055)

0.072 (0.102)

0.008 (0.012)

0.063 (0.097)

0.087 (0.055)

0.001 (0.002)

Pr(Y) = 0.023

Any Nursing Home Care

p-val≤0.05

++

p-val≤ 0.10

+

Pr(long-term care insurance) in these data = 0.157. 2SRI – sres: 2SRI with standardized residuals; 2SRI – dres: 2SRI with deviance residuals; 2SRI – ares: 2SRI with Anscombe residuals

Pr(Y) = 0.43

Pr(Y) = 0.60

Estimators

Informal Care from Child

Informal Care from Any Source

Outcomes→

Author Manuscript

Effects of long-term care insurance on different outcomes.

Author Manuscript
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